page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Kanamycin injection (Kantrex)

Category:

  • Antibiotic

Description:

  • Aminoglycoside antibiotic

Indications:

  • Serious infections (P. aeruginosa, Proteus species, E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, Staphylococcus species)

  • Bacterial neonatal sepsis

  • Bacterial septicemia

  • Serious bacterial infections of the CNS (meningitis)

  • Urinary tract, respiratory tract, skin, bone and soft tissue (including burns) infections

  • Gram-negative infections

  • Emperic therapy for unknown serious infections

  • Unlabeled use:

    • multi-drug regimen for Mycobacterium avium complex infections

Contraindications:

  • Generally not indicated for long-term therapy due to nephrotoxocity and ototoxicity

Precautions:

  • Pregnancy category D

  • May cause nephrotoxicity, therefore closely monitor renal function, especially in elderly patients.

  • May cause ototoxicity, therefore monitor hearing

  • Monitor peak and trough serum concentrations

  • In patients with extensive burns, altered pharmacokinetics may alter serum concentrations.

  • May produce hypomagnesemia, especially if poor or restricted diet.

  • Aminoglycosides have neuromuscular blockade activity with a curare-like effect.  Monitor patient’s neuromuscular function, especially in patients with myasthenia gravis, parkinsonism or infant botulism.

  • Administer over 30-60 minute infusion

Adverse Reactions (Side Effects):

  • Renal: oliguria, proteinuria, increased creatinine and BUN

  • Miscellaneous: apnea

  • Pain at injection site

  • Granular casts

  • “Malabsorption syndrome” characterized by increase in fetal fat, decrease in serum carotene and fall in xylose absorption

Dosage:

  • Administered by IM or IV injection

  • Do not exceed 1.5 grams per day by any route

  • Adults:

    • 1.5mg/kg/day divided into 2-3 equal doses

  • Aerosol treatment:

    • 250mg 2-4 times a day, diluted with 3mL of normal saline

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site